X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the clinical advancement of GT-002, which is a small molecule GABAA receptor-positive allosteric Modulator. Currently, it is being evaluated for the treatment of schizophrenia.
Lead Product(s): GT-002
Therapeutic Area: Psychiatry/Psychology Product Name: GT-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Centre for Neuropsychiatric Schizophrenia Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 10, 2024
Details:
GT-002 is an oral small molecule GABAA receptor Positive Allosteric Modulator eliciting both tonic and phasic inhibitory currents. It restores ketamine induced cognitive deficits in patients with schizophrenia.
Lead Product(s): GT-002
Therapeutic Area: Psychiatry/Psychology Product Name: GT-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
